NASDAQ:ALLO

Allogene Therapeutics Stock Insider Trading

etoro logo Buy ALLO
*Your capital is at risk
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026

Allogene Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 42.16. In total, the insiders bought 19.78M and sold 730.17K ALLO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
42.16
Buy 19.78M shares
Sell 730.17K shares
66% Buy Activity
Moderate Positive Correlation
Sell Signal Low Confidence
Mar 16, 2026

Analysis Breakdown:

  • Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 42.16.
  • Partially supported by a positive historical correlation.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Jan 21, 2026
Sell
Common Stock
S-Sale
Roberts Zachary
EVP Of R&d
Officer 26 269
Value: $41.0K
Dec 18, 2025
Buy
Restricted Stock Unit
M-Exempt
Kazam Joshua A
Director
Director 47 700
Value: $67.7K
Dec 18, 2025
Buy
Common Stock
M-Exempt
Kazam Joshua A
Director
Director 47 700
Value: $67.7K
Nov 17, 2025
Sell
Common Stock
S-Sale
Beneski Benjamin Machinas
SVP, Chief Technical Officer
Officer 786
Value: $959
Oct 21, 2025
Sell
Common Stock
S-Sale
Parker Geoffrey M.
Chief Financial Officer
C-Suite Officer 36 744
Value: $46.2K
Jun 18, 2025
Buy
Stock Option (Right to buy)
A-Award
Sato Vicki L
Director
Director 144 400
Value: $186.3K
Jun 18, 2025
Buy
Restricted Stock Unit
A-Award
Messemer Deborah M.
Director
Director 95 400
Value: $123.1K
Jun 18, 2025
Buy
Restricted Stock Unit
A-Award
Humer Franz B
Director
Director 95 400
Value: $123.1K
Jun 18, 2025
Buy
Restricted Stock Unit
A-Award
Barrett Elizabeth A.
Director
Director 95 400
Value: $123.1K
Jun 18, 2025
Buy
Restricted Stock Unit
A-Award
Mayo Stephen
Director
Director 95 400
Value: $123.1K
Jun 18, 2025
Buy
Restricted Stock Unit
A-Award
Witte Owen N.
Director
Director 95 400
Value: $123.1K
Jun 18, 2025
Buy
Restricted Stock Unit
A-Award
Kazam Joshua A
Director
Director 94 500
Value: $121.9K
Jun 18, 2025
Buy
Restricted Stock Unit
A-Award
Kazam Joshua A
Director
Director 94 500
Value: $121.9K
Jun 18, 2025
Buy
Restricted Stock Unit
A-Award
Witte Owen N.
Director
Director 95 400
Value: $123.1K
Jun 18, 2025
Buy
Restricted Stock Unit
A-Award
Mayo Stephen
Director
Director 95 400
Value: $123.1K
Jun 18, 2025
Buy
Restricted Stock Unit
A-Award
Barrett Elizabeth A.
Director
Director 95 400
Value: $123.1K
Jun 18, 2025
Buy
Restricted Stock Unit
A-Award
Humer Franz B
Director
Director 95 400
Value: $123.1K
Jun 18, 2025
Buy
Restricted Stock Unit
A-Award
Messemer Deborah M.
Director
Director 95 400
Value: $123.1K
Jun 18, 2025
Buy
Stock Option (Right to buy)
A-Award
Sato Vicki L
Director
Director 144 400
Value: $186.3K
Jun 10, 2025
Sell
Common Stock
S-Sale
Messemer Deborah M.
Director
Director 36 885
Value: $52.4K
Jun 10, 2025
Sell
Common Stock
S-Sale
Messemer Deborah M.
Director
Director 36 885
Value: $52.4K
Apr 21, 2025
Sell
Common Stock
S-Sale
Yoshiyama Annie
SVP, Finance
Officer 9 601
Value: $13.5K
Apr 21, 2025
Sell
Common Stock
S-Sale
Yoshiyama Annie
SVP, Finance
Officer 9 601
Value: $13.5K
Mar 14, 2025
Sell
Common Stock
S-Sale
Chang David D
President And CEO
CEO / President 46 668
Value: $91.5K
Mar 14, 2025
Sell
Common Stock
S-Sale
Beneski Benjamin Machinas
SVP, Chief Technical Officer
Officer 5 488
Value: $10.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT ALLOGENE THERAPEUTICS INC.
Allogene Therapeutics
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE